Section Arrow
TRAW.NASDAQ
- Traws Pharma Inc
(Financial Status)
Quotes are at least 15-min delayed:2026/09/04 09:34 EDT
Regular Hours
Last
 0.5661
+0.0241 (+4.45%)
Day High 
0.5711 
Prev. Close
0.542 
1-M High
0.625 
Volume 
1.88K 
Bid
0.5522
Ask
0.61
Day Low
0.5661 
Open
0.5711 
1-M Low
0.482 
Market Cap 
8.33M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.57 
20-SMA 0.56 
50-SMA 0.61 
52-W High 3.265 
52-W Low 0.4301 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.83/-0.59
Enterprise Value
8.33M
Balance Sheet
Book Value Per Share
0.11
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
2.79M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
IMRNImmuron Limited1.88+0.77+69.37%-- 
CMNDClearmind Medicine Inc.1.5101-0.1899-11.17%-- 
CABACabaletta Bio3.53+0.05+1.44%-- 
MRNAModerna151.705+2.835+1.90%-- 
RAREUltragenyx Pharmaceutical15.685+0.835+5.62%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.